| Name | VER49009 |
| Description | VER49009 (CCT0129397) is an effective HSP90 inhibitor(IC50 =25 nM, Kd=78 nM). |
| Cell Research | Antiproliferative effects are measured using the sulforhodamine B assay. HUVEC sensitivity is determined by an alkaline phosphatase method. (Only for Reference) |
| Kinase Assay | Fluorescence Polarization Assay: Binding of HSP90 inhibitors to human full-length recombinant HSP90β is determined by a competitive binding fluorescence polarization assay, using a fluorescent pyrazole resorcinol probe. |
| In vitro | In the human ovarian tumor model, intraperitoneal injection of VER-49009 (4 mg/kg) can induce the dissociation of HSP90 and ERBB2. In athymic mice, intravenous injection of VER-49009 (20 mg/kg) demonstrates efficacy. |
| In vivo | VER-49009 can induce the dissociation of HSP72 and HSP27 from their binding proteins, leading to cell cycle arrest. In recombinant yeast Hsp90 protein (IC50 = 167 nM), VER-49009 inhibits the endogenous ATPase activity. During the treatment of liver fibrosis, VER-49009 induces the accumulation of hepatic stellate cells (CFSC) in the G2 phase, inhibiting cell growth. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 71 mg/mL (183.1 mM)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | VER49009 | CCT 0129397 | CCT-0129397 |
| Inhibitors Related | Ethoxyquin | SNX0723 | Tamoxifen | DN401 | SNX2112 | Ganetespib | Teprenone | Elesclomol | Rifabutin | Palmitic acid | Paeoniflorin | Tamoxifen Citrate |
| Related Compound Libraries | Apoptosis Compound Library | Endoplasmic Reticulum Stress Compound Library | HIF-1 Signaling Pathway Compound Library | Anti-Breast Cancer Compound Library | CNS-Penetrant Compound Library | Oxidation-Reduction Compound Library |
United States
